8-K: Sangamo Therapeutics Announces $23 Million Underwritten Offering of Common Stock and Warrants

Sangamo Therapeutics has entered into an underwriting agreement for a $23 million offering of common stock and warrants.

Summary

• Sangamo Therapeutics, Inc. has entered into an underwriting agreement for the issuance and sale of 12,235,000 shares of common stock and pre-funded warrants to purchase 34,398,393 shares of common stock.
• Accompanying these securities are warrants to purchase 46,633,393 shares of common stock.
• The combined offering price is $0.50 for each share of common stock and accompanying purchase warrant, and $0.49 for each pre-funded warrant and accompanying purchase warrant.
• The gross proceeds to the company are expected to be approximately $23.0 million before deducting underwriting discounts and estimated offering expenses.
• The offering is expected to close on May 14, 2025, subject to customary closing conditions.
• Pre-funded warrants have an exercise price of $0.01 per share and are exercisable immediately until fully exercised.
• Purchase warrants have an exercise price of $0.75 per share, exercisable six months after issuance and expiring six years after issuance.
• Holders are limited to owning no more than 4.99% of the company's outstanding common stock after exercising warrants, which can be increased to 19.99% with 61 days' notice.
• Sangamo has the option to force the exercise of the purchase warrants if the weighted-average price of the common stock exceeds $2.75 for ten consecutive trading days after six months from the issuance date.
• The offering is made pursuant to an effective registration statement on Form S-3.

Sentiment

Score: 4

Explanation: While the capital raise provides necessary funding, the terms are not particularly favorable for existing shareholders due to the dilution and low offering price. The use of warrants adds potential future dilution.

Positives

• The offering will provide Sangamo with approximately $23.0 million in gross proceeds to fund its operations.
• The pre-funded warrants allow investors to participate in the company's growth with a low exercise price of $0.01.
• The company has the option to force warrant exercise if the stock price appreciates significantly, potentially bringing in additional capital.

Negatives

• The offering will dilute existing shareholders' ownership.
• The exercise of warrants could further dilute shareholders in the future.
• The offering price of $0.50 per share may be perceived as low, potentially indicating a need for capital at a less favorable valuation.

Risks

• The closing of the offering is subject to customary closing conditions and may not occur.
• The company's stock price may be negatively impacted by the offering.
• Future events could affect the company's ability to meet its obligations under the underwriting agreement and warrants.

Future Outlook

The company expects to complete the offering on May 14, 2025, subject to customary closing conditions, and intends to use the net proceeds as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus under the heading Use of Proceeds.

Industry Context

This type of capital raise is common in the biotech industry, particularly for companies in the clinical stage that require funding for research and development. The use of warrants is a way to attract investors who may be interested in potential future upside.

Comparison to Industry Standards

• Comparable companies in the biotech sector, such as CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics, have also utilized public offerings of common stock and warrants to raise capital.
• The terms of this offering, including the offering price and warrant coverage, are generally consistent with industry standards for companies with similar market capitalizations and development pipelines.
• For example, a similar offering by a peer company might involve a combined offering price of around 10-20% below the current market price, with warrants representing the right to purchase shares at a premium of 50-100% to the offering price.

Stakeholder Impact

• Shareholders will experience dilution of their ownership.
• The company will have additional capital to fund its operations and research and development.
• Potential warrant holders have the opportunity to invest in the company's future growth.

Next Steps

• The company expects to close the offering on May 14, 2025, subject to customary closing conditions.
• The company will use the net proceeds from the sale of the Securities (including any cash exercise of the Pre-Funded Warrants or the Warrants) as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus under the heading Use of Proceeds.
• The Company will use its best efforts to list the Shares, the Pre-Funded Warrant Shares and the Warrant Shares on the Nasdaq Market.

Key Dates

Keywords

Sangamo Therapeutics, underwriting agreement, common stock, warrants, pre-funded warrants, offering, capital raise, Cantor Fitzgerald, dilution